Download PDFPDF

Automated virtual reality (VR) cognitive therapy for patients with psychosis: study protocol for a single-blind parallel group randomised controlled trial (gameChange)
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Protocol alteration: change of primary outcome measure due to the pandemic
    • Daniel Freeman, Professor of Clinical Psychology and gameChange Chief Investigator University of Oxford
    • Other Contributors:
      • Ariane Petit, Trial co-ordinator
      • Ly-Mee Yu, Associate Professor and Deputy Director Academic (Primary Care Clinical Trials Unit). gameChange trial lead statistician

    The original primary outcome

    The gameChange trial primary outcome was avoidance and distress in real-life situations measured using a behavioural assessment task (Oxford-Behavioural Assessment Task, O-BAT). The O-BAT is administered with a trial research assistant and the patient is asked to go into a (personalised) hierarchy of five real world situations that they find anxiety-provoking (e.g. go into a local café or shop). The assessment records how many of the five steps the individual completed (avoidance score) and their level of anxiety (distress score).

    Why the measure had to be changed

    Due to the COVID-19 lockdown measures implemented in March 2020, we were not allowed to administer the O-BAT. It would involve face-to-face contact, which was prohibited by the NHS trusts. It was also the case that many locations (e.g. cafes, shops) used in the O-BAT were closed. All patient recruitment into the trial was suspended for six months but remote assessments continued for those who had already entered into the trial.

    The replacement primary outcome

    We had already developed a self-report version of the O-BAT, which was a secondary outcome measure. In the published protocol this is called the ‘self-report O-BAT’. We now call the measure the Oxford Agoraphobic Avoidance Scale (O-AS) (Lambe et al, submitted). We have made this self-report version of the O-BAT the primary outcome variable. As in the original O-BAT, the O-AS gives an avoidance...

    Show More
    Conflict of Interest:
    DF is a founder and non-executive board director of Oxford VR, a University of Oxford spin-out company, which has programmed the gameChange treatment and will commercialise it.